# Azienda Ospedaliera San Camillo-Forlanini

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/azienda-ospedaliera-san-camillo-forlanini/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 67 |
| Citations | 84,884 |
| City | Rome |
| Country | IT |
| Description | Azienda Ospedaliera San Camillo-Forlanini is a research organisation in Rome, IT. OpenAlex records 2,200 works and 84,884 citations for it. 473 researchers list it as their most recent affiliation. |
| Homepage | http://www.scamilloforlanini.rm.it/html/ |
| OpenAlex ID | https://openalex.org/I4210095143 |
| Researchers | 473 |
| ROR ID | https://ror.org/00j707644 |
| Type | healthcare |
| Works | 2,200 |

## University papers

Showing 12 of 13.

- [Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target](https://scholariq.org/papers/selecting-therapeutic-targets-in-inflammatory-bowel-disease-stride-determining/)
- [ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications](https://scholariq.org/papers/ecco-esgar-guideline-for-diagnostic-assessment-in-ibd-part-1-initial-diagnosis/)
- [ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-crohn-s-disease-medical-treatment/)
- [ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-crohn-s-disease-surgical-treatment/)
- [ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-ulcerative-colitis-medical-treatment/)
- [ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-ulcerative-colitis-surgical-treatment/)
- [A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis](https://scholariq.org/papers/a-randomized-double-blind-placebo-controlled-parallel-group-enriched-design/)
- [ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects](https://scholariq.org/papers/ecco-esgar-guideline-for-diagnostic-assessment-in-ibd-part-2-ibd-scores-and/)
- [ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-crohn-s-disease-medical-treatment-2/)
- [Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study](https://scholariq.org/papers/outcomes-of-covid-19-in-79-patients-with-ibd-in-italy-an-ig-ibd-study/)
- [Development of the Lémann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease](https://scholariq.org/papers/development-of-the-lemann-index-to-assess-digestive-tract-damage-in-patients/)
- [ECCO Guidelines on Inflammatory Bowel Disease and Malignancies](https://scholariq.org/papers/ecco-guidelines-on-inflammatory-bowel-disease-and-malignancies/)

## University top topics

Showing 8 of 25.

- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.